Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 24Carcinoma, Transitional Cell 6Urinary Bladder Neoplasms 3Carcinoma, Renal Cell 3Small Cell Lung Carcinoma 2Sarcoma 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 2Lung Neoplasms 2Disease 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Brain Neoplasms 2mCRPC (Metastatic Castration-resistant Prostate Cancer) 1Uterine Cervical Neoplasms 1Tuberous Sclerosis 1Thyroid Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Rectal Neoplasms 1Prostate Cancer Metastatic 1Ovarian Neoplasms 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1

Interventions

enzalutamide 7Prednisone 7cabazitaxel 6Radiosurgery 6Docetaxel 5Androgen Antagonists 4Abiraterone Acetate 4XRP6258 2Standard of Care 2talazoparib 1sipuleucel-T 1rucaparib 1pembrolizumab 1olaparib 1gallium 68 PSMA-11 1fludrocortisone acetate 1darolutamide 1apalutamide 1Zuclomiphene 1Radiotherapy, Image-Guided 1Radiotherapy 1Prednisolone 1Positron Emission Tomography Computed Tomography 1Pluvicto 1Midazolam 1Lutetium-177 1Lutetium 1Lenograstim 1LY3023414 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostate Cancer Metastatic × Injections × Genitourinary × Clear all
NCT04028388 2024-04-17

ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

Modra Pharmaceuticals

Phase 2 Completed
135 enrolled 29 charts
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡